AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $54.64.

A number of analysts have commented on the stock. Truist Financial upped their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. HC Wainwright decreased their price objective on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. UBS Group lifted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a report on Thursday. Finally, JPMorgan Chase & Co. lowered their price target on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th.

Insider Activity

In other AnaptysBio news, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the transaction, the insider now directly owns 7,020 shares of the company’s stock, valued at $279,536.40. This represents a 55.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 72.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock worth $892,936 in the last three months. 33.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new stake in AnaptysBio during the first quarter worth approximately $38,000. Values First Advisors Inc. bought a new stake in shares of AnaptysBio during the 3rd quarter worth $49,000. nVerses Capital LLC grew its stake in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the last quarter. Headlands Technologies LLC raised its holdings in AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 2,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 2,600 shares during the last quarter.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $19.00 on Friday. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31. The business’s fifty day moving average is $31.06 and its two-hundred day moving average is $29.87. The stock has a market capitalization of $578.17 million, a P/E ratio of -3.13 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, research analysts forecast that AnaptysBio will post -6.09 earnings per share for the current year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.